Allergan Receives Positive Opinion for GANFORT(R) (LUMIGAN(R)/Timolol Combination) in European Union

GANFORT(R) is indicated for reduction of intraocular pressure(IOP) in patients with open-angle glaucoma or ocular hypertension whoare insufficiently responsive to topical beta-blockers orprostaglandin analogues.

"Adherence to therapy is an integral factor in the successfultreatment of glaucoma and ocular hypertension. Combination therapiesoften reduce the number of medications required and can aid patientswith compliance," said Dr. Scott Whitcup, Allergan's Executive VicePresident, Research & Development. "We are very pleased to havereceived this positive opinion for GANFORT(R) in the European Unionand to present physicians and their patients with this latest advancein combination therapy for the treatment of glaucoma, a leading causeof preventable blindness worldwide."

About Allergan, Inc.

Allergan, Inc., with headquarters in Irvine, California, is atechnology-driven, global specialty pharmaceutical and medical devicecompany that develops and commercializes innovative products for theophthalmology, neurosciences, medical dermatology, medical aestheticsand other specialty markets. Allergan is dedicated to delivering valueto its customers, satisfying unmet medical needs, and improvingpeople's lives.

Forward-Looking Statements

This press release contains "forward-looking statements,"including, among other statements, the statements by Dr. Whitcup,statements regarding research and development outcomes, efficacy, andmarket and product potential. These statements are based on currentexpectations of future events. If underlying assumptions proveinaccurate or unknown risks or uncertainties materialize, actualresults could vary materially from Allergan's expectations andprojections. Risks and uncertainties include general industry andpharmaceutical market conditions; general domestic and internationaleconomic conditions, such as interest rate and currency exchange ratefluctuations; technological advances and patents obtained bycompetitors; challenges inherent in product marketing such as theunpredictability of market acceptance for new pharmaceutical andbiologic products and/or the acceptance of new indications for suchproducts; domestic and foreign health care reforms; the timing anduncertainty of the research and development and regulatory processes;trends toward managed care and health care cost containment; andgovernmental laws and regulations affecting domestic and foreignoperations. Allergan expressly disclaims any intent or obligation toupdate these forward-looking statements except as required to do so bylaw.

Additional information concerning these and other risk factors canbe found in press releases issued by Allergan, as well as Allergan'spublic periodic filings with the Securities and Exchange Commission,including the discussion under Item 1A of Part I, "Risk Factors," inAllergan's 2005 Form 10-K. Copies of Allergan's press releases andadditional information about Allergan is available on the World WideWeb at www.allergan.com or you can contact the Allergan InvestorRelations Department by calling 1-714-246-4636.